DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20172120

Study of effect of myoinositol on menstrual irregularities and skin problems in polycystic ovarian syndrome cases

Monika Ranwa, Tripti Nagaria, Jyoti Jaiswal, Abhishek Arya

Abstract


Background: Polycystic ovary syndrome (PCOS), first identified in 1935 as Stein-Leventhal syndrome, is a complex neuro-endocrine disorder affecting approximately 5% to 10% of women reproductive age. Typically PCOS is characterized by hyperandrogenism (extremely variable in its occurrence), chronic anovulation, polycystic ovaries at ultrasound evaluation and dermatological problems such as acne, hirsute and seborrhoea. PCOS is indeed the most common cause of female infertility.

Methods: This prospective interventional study was conducted during December 2012 to June 2013 in Department of Obstetrics and Gynaecology at Pt. Jawaharlal Nehru Memorial Medical College and Associated Dr. Bhim Rao Ambedkar Memorial Hospital, Raipur (C.G.) India, after obtaining permission of ethical committee of institute. All young girls and married women who attended GOPD of Department of Obstetrics and Gynaecology having polycystic ovarian syndrome as defined by Rotterdam Criteria were registered and screened for inclusion in the study. At the end of three months’ data were compiled in MS-Excel and checked for its completeness and correctness then it was analysed suitable statistical test was applied and p-value <0.05 was considered statistically significant.

Results: Maximum no of cases were between 21 to 25 yrs age, youngest one was of 15 yrs and oldest one was of 33 yrs. 72% cases belonged to urban area and only 28% cases belonged to rural area. 94.67% of cases were presented with abnormal menstrual cycle. The most common menstrual abnormality was Oligomenorrhoea (43.66%) followed by Oligomenorrhoea+Menorrhagia (21.13%) than Amenorrhoea (19.71%) and Hypomenorrhoea+Oligomenorrhoea (15.49%). 42.7% cases had oily skin, 26.7% cases had hirsutism, 20% cases had acne and 9.3% cases had acanthosis nigricans. 74.65% cases (53/75) were improved in their menstrual complaints; most common menstrual abnormality improved was Oligomenorrhoea+ Menorrhagia i.e. 88.67% (13/15). Out of all cases of oligomenorrhoea 77.4% cases (24/31) achieved regular menses. Out of all cases of oligomenorrhoea+ hypomenorrhoea 81.8%% cases (2/11) achieved regular menses.

Conclusions: Present study confirms that Myoinositol, an insulin sensitizer, by improving insulin signalling reduces insulin resistance and improves menstrual irregularities and skin problems of PCOS cases.


Keywords


Menstrual irregularity, Myoinositol, PCOS, Skin problems

Full Text:

PDF

References


Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term PCOS according to the Rotterdam consensus criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19-25.

Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352:1223-36.

Nelson VL, Qin KN, Rosenfield RL, Wood JR, Penning TM, Legro RS et al. The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab. 2001;86:5925-33.

Rosenbaum D, Haber RS, Dunaif A. Insulin resistance in polycystic ovary syndrome: decreased expression of GLUT-4 glucose transporters in adipocytes. Am J Physiol. 1993;264:197-202.

Kennington AS, Hill CR, Craig J, Bogardus C, Raz I, Ortmeyer HK et al. Low urinary chiro-inositol excretion in non-insulin-dependent diabetes mellitus. N Engl J Med. 1990;323:373-8.

Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiroinositol) for polycystic ovary syndrome. Cochrane Database Syst Rev. 2003;(3):CD003053.

Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G. Ovulatory and metaboliceffects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med. 1999;340:1314-20.

Papaleo E, Unfer V, Baillargeon JP, De Santis L, Fusi F, Brigante C et al. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecol Endocrinol. 2007;23:700-3.

Cohen P. The twentieth century struggle to decipher insulin signalling. Nat Rev Mol Cell Biol. 2006;7:867-73.

Baillargeon JP, Nestler JE, Ostlund RE, Apridonidze T, DiamantiKandarakis E. Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolism. Hum Reprod. 2008;23:1439-46.

Eshre TR, ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41-7.

Papaleo E, Unfer V, Baillargeon JP, De Santis L, Fusi F, Brigante C et al. Myoinositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecol Endocrinol. 2007;23:700-3.

Gerli S, Papaleo E, Ferrari A, Di Renzo GC. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci. 2007;11:347-54.

Genazzani AD, Lanzoni C, Ricchieri F, Jasonni Vm. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol. 2008;24:139-44.

Venturella R, Mocciaro R, De Trana E, D'Alessandro P, Morelli M, Zullo F. Assessment of the modification of the clinical, endocrinal and metabolic profile of patients with PCOS syndrome treated with myo-inositol. Minerva Ginecol. 2012;64(3):239-43.

Le Donne M, Alibrandi A, Giarrusso R, Lo Monaco I, Muraca U. Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: effects on body composition. Minerva Ginecol. 2012;64(1):23-9.

Liao L, Tian YJ, Zhao JJ, Xin Y, Xing HY, Dong JJ. Metformin versus metformin plus rosiglitazone in women with polycystic ovary syndrome. Chin Med J. 2011;124(5):714-8.

Raffone E, Rizzo P, Benedetto V. Insulin sensitiser agents alone and in cotreatment with r-FSH for ovulation induction in PCOS women. Gynecol Endocrinol. 2010;26(4):275-80.

Minozzi M, Costantino D, Guaraldi C, Unfer V. The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome. Gynecol Endocrinol 2011;27(11):920-4.

Zacche MM, Caputo L, Filippis S, Zacche G, Dindelli M, Ferrari A. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol Endocrinol 2009;25: 508-13.

Genazzani AD, Prati A, Santagni S, Ricchieri F, Chierchia E, Rattighieri E. Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. Gynecol Endocrinol. 2012;28(12):969-73.

Cho LW, Kilpatrick, Keevil BG, Coday AM, Atkin SL. Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovarion syndrome. Clinical Endocrinol. 2009;70:233-7.

Kazerooni T, Shojaei-Baghini A, Dehbashi S, Asadi N, Ghaffarpasand F, Kazerooni Y. Effects of metformin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, double-blind, placebo-controlled study; Fertil Steril. 2010;94(6):2208-13.